This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why Momentum in BioLife Solutions (BLFS) Should Keep going
by Zacks Equity Research
BioLife Solutions (BLFS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Are Medical Stocks Lagging Eli Lilly (LLY) This Year?
by Zacks Equity Research
Here is how Eli Lilly (LLY) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.
Here's What Could Help BioLife Solutions (BLFS) Maintain Its Recent Price Strength
by Zacks Equity Research
BioLife Solutions (BLFS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year?
by Zacks Equity Research
Here is how BioLife Solutions, Inc. (BLFS) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions (BLFS) delivered earnings and revenue surprises of 57.14% and 19.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of -59.26% and 2.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Owens & Minor (OMI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 9.09% and 0.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 2.46% and 0.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What Makes BioLife Solutions (BLFS) a Good Fit for 'Trend Investing'
by Zacks Equity Research
BioLife Solutions (BLFS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase
by Zacks Equity Research
BioLife's (BLFS) latest product, CryoCase, is compatible with various downstream processing systems, including its own Signata CT-5.
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions (BLFS) delivered earnings and revenue surprises of 26.92% and 8.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 14.29% and 2.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (BLFS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
BioLife Solutions (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific (BSX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 9.80% and 4.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for October 9th
by Zacks Equity Research
BLFS, BWMN and FTEK have been added to the Zacks Rank #5 (Strong Sell) List on October 9, 2023.
New Strong Sell Stocks for September 13th
by Zacks Equity Research
BLFS, ALCO and AFCG have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2023.
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 10.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 6.72% and 3.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -60% and 12.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Lantheus Holdings (LNTH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 13.95% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Rises 9.7% in a Year: More Room for Growth?
by Zacks Equity Research
Humana's (HUM) individual Medicare Advantage membership growth is likely to boost premium income.
Encompass Health's (EHC) 155th Hospital Opens in Wisconsin
by Zacks Equity Research
The Rehabilitation Hospital of Western Wisconsin is Encompass Health's (EHC) first location in the state.
Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how BioLife Solutions, Inc. (BLFS) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.
UnitedHealth (UNH) Plan in Indiana to Offer Pathways Program
by Zacks Equity Research
UnitedHealth (UNH) expects the new Pathways for Aging program to serve around 100,000 people.
Brookdale Senior (BKD) February Weighted Average Occupancy Up
by Zacks Equity Research
Brookdale Senior Living (BKD) witnesses 16 straight months of year-over-year increases in weighted average occupancy level.